Larvol Delta - Ascletis-Announces-Initiation-of-Two-Phase-I-Studies-in-US-for-the-Treatment-of-Obesity-ASC36-OnceMonthly-Injection-an-Amylin-Receptor-Peptide-Agonist-and-ASC36_35FDC-OnceMonthly-Injection-a-CoFormulation-of-ASC36-and-GLP1RGIPR-Peptide-Agonist-ASC35

ASC36i - Ascletis

ASC36_35 FDC - Ascletis

https://www.manilatimes.net/2026/08/10/tmt-newswire/pr-newswire/ascletis-announces-initiation-of-two-phase-i-studies-in-us-for-the-treatment-of-obesity-asc36-once-monthly-injection-an-amylin-receptor-peptide-agonist-and-asc3635fdc-once-monthly-injection-a-co-formulation-of-asc36-and-glp-1rgipr-peptide-agonist-asc35/2401942

Aug 10, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next